Literature DB >> 11044724

Block of the alpha9 nicotinic receptor by ototoxic aminoglycosides.

C V Rothlin1, E Katz, M Verbitsky, D E Vetter, S F Heinemann, A B Elgoyhen.   

Abstract

In the present study, we report that the alpha9 nicotinic acetylcholine receptor (nAChR) expressed in Xenopus laevis oocytes is reversibly blocked by aminoglycoside antibiotics. The aminoglycosides tested blocked the alpha9 nAChR in a concentration-dependent manner with the following rank order of potency: neomycin>gentamicin>streptomycin>amikacin>kanamycin. The antagonistic effect of gentamicin was not overcome by increasing the concentration of acetylcholine (ACh), indicative of a non-competitive type of block. Blockage of ACh-evoked currents by gentamicin was found to be voltage-dependent, being more potent at hyperpolarized than at depolarized holding potentials. Furthermore, gentamicin blockage was dependent upon the extracellular Ca(2+) concentration, shown by the fact that increments in extracellular Ca(2+) significantly reduced the potency of this aminoglycoside to block the alpha9 nAChR. Possible mechanisms of blockage by the aminoglycosides are discussed. The present results suggest that the initial reversible actions of aminoglycosides at the organ of Corti, such as the elimination of the olivocochlear efferent function, are due in part to the interaction with the native alpha9-containing cholinergic receptor of the outer hair cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044724     DOI: 10.1016/s0028-3908(00)00056-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

1.  Effects of medial olivocochlear efferent stimulation on the activity of neurons in the auditory midbrain.

Authors:  Kumar Seluakumaran; Wilhelmina H A M Mulders; Donald Robertson
Journal:  Exp Brain Res       Date:  2007-11-27       Impact factor: 1.972

Review 2.  The efferent medial olivocochlear-hair cell synapse.

Authors:  Ana Belén Elgoyhen; Eleonora Katz
Journal:  J Physiol Paris       Date:  2011-07-06

3.  Positive modulation of the α9α10 nicotinic cholinergic receptor by ascorbic acid.

Authors:  J C Boffi; C Wedemeyer; M Lipovsek; E Katz; D J Calvo; A B Elgoyhen
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 4.  Prestin and the cholinergic receptor of hair cells: positively-selected proteins in mammals.

Authors:  Ana Belén Elgoyhen; Lucía F Franchini
Journal:  Hear Res       Date:  2010-01-06       Impact factor: 3.208

5.  Alterations in the cholinergic system of brain stem neurons in a mouse model of Rett syndrome.

Authors:  Max F Oginsky; Ningren Cui; Weiwei Zhong; Christopher M Johnson; Chun Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2014-07-09       Impact factor: 4.249

6.  Voltage-dependent inhibition of rat skeletal muscle sodium channels by aminoglycoside antibiotics.

Authors:  Adrian J Yeiser; James R Cox; Sterling N Wright
Journal:  Pflugers Arch       Date:  2004-02-13       Impact factor: 3.657

7.  Gentamicin abolishes all cochlear effects of electrical stimulation of the inferior colliculus.

Authors:  W H A M Mulders; D Robertson
Journal:  Exp Brain Res       Date:  2006-03-10       Impact factor: 1.972

8.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.

Authors:  Igor Nudelman; Annie Rebibo-Sabbah; Marina Cherniavsky; Valery Belakhov; Mariana Hainrichson; Fuquan Chen; Jochen Schacht; Daniel S Pilch; Tamar Ben-Yosef; Timor Baasov
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

9.  Genome-wide characterisation of the binding repertoire of small molecule drugs.

Authors:  Lee Makowski; Diane J Rodi
Journal:  Hum Genomics       Date:  2003-11       Impact factor: 4.639

10.  On the interaction of neomycin with the slow vacuolar channel of Arabidopsis thaliana.

Authors:  Joachim Scholz-Starke; Armando Carpaneto; Franco Gambale
Journal:  J Gen Physiol       Date:  2006-03       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.